UMP Healthcare Holdings Limited (0722) AI Stock Analysis

• Market Cap: HK$380.45M
• Dividend Yield: 7.1%
• Average Volume (3M): 28.76K
• Price to Earnings (P/E): 11.9
• Beta (1Y): 0.17
• Revenue Growth: -2.88%
• EPS Growth: -22.83%
• Country: HK
• Employees: 453
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.02
• Shares Outstanding: 810,955,260
• 10 Day Avg. Volume: 39,200
• 30 Day Avg. Volume: 28,758
• PEG Ratio: -0.56
• Price to Book (P/B): 0.51
• Price to Sales (P/S): 0.52
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 78 Outperform
• Price Target: HK$0.50 ▲(4.17% Upside)

The stock's strong valuation and technical indicators are the most significant positive factors. Financial performance is solid, with growth and operational efficiency, though there is room for improvement in return on equity. The absence of earnings call data and corporate events has no impact on the score.

Positive Factors

Governance Enhancement

Improved governance structure with diverse board and committees strengthens decision-making and stakeholder trust, positively impacting long-term strategy.

Cash Generation

Strong cash generation enhances operational flexibility and supports strategic investments, ensuring sustainable business growth.

Revenue Growth

Consistent revenue growth indicates the company's ability to expand its market presence and enhance service offerings, supporting long-term financial health.

Negative Factors

Debt-to-Equity Increase

An increase in debt-to-equity ratio, although slight, could signal rising leverage, which may constrain financial flexibility if not managed prudently.

Return on Equity Decline

Lower ROE indicates reduced efficiency in generating returns on shareholder investments, potentially impacting investor confidence and future capital raising.

Net Profit Margin Decline

A declining net profit margin suggests pressure on profitability, which could affect the company's ability to reinvest in growth and maintain competitive positioning.

UMP Healthcare Holdings Limited Business Overview & Revenue Model

Company Description

UMP Healthcare Holdings Limited, an investment holding company, provides a range of medical and healthcare services in Hong Kong, Macau, and Mainland China. It operates in two segments, Corporate Healthcare Solution Services and Clinical Healthcare Services. The company offers virtual care; family medicine; specialist consultation services, including internal medicine, surgery, pediatrics, cardiology, dermatology, otorhinolaryngology, orthopedics, ophthalmology, urology, gastroenterology and hepatology, radiology, endocrinology, and diabetes; and dental care services, such as dental implant, cosmetic dentistry, periodontal treatments, and orthodontics, as well as traditional Chinese medicines. It also provides physiotherapy services comprises muscle-strengthening, limb function, eye-hand coordination, and hand function trainings; day surgery and endoscopy; diagnostic imaging and laboratory; health assessment; visa medical examination; vaccination and consultation; vision care and optometry; plastic, head, and neck surgeries; dermatology and aesthetics; chronic disease management; and COVID-19 screening test services. In addition, the company engages in the provision of healthcare training and consultation services. It serves insurance companies and corporations, and self-paid patients. The company operates a network of approximately 1,100 self-owned and affiliated service points. UMP Healthcare Holdings Limited was founded in 1990 and is headquartered in Central, Hong Kong.

How the Company Makes Money

UMP Healthcare makes money primarily through its extensive network of medical centers and clinics, which provide various healthcare services to patients. The company generates revenue through patient consultations, medical examinations, and specialty healthcare services. Additionally, UMP Healthcare has partnerships with corporate clients and insurance companies, offering tailored healthcare plans and services that contribute significantly to its income. The company also benefits from its preventive healthcare programs and health management services, which are designed to meet the growing demand for comprehensive healthcare solutions.

UMP Healthcare Holdings Limited Financial Statement Overview

Summary

UMP Healthcare Holdings Limited demonstrates strong revenue growth and operational efficiency, with stable cash flow generation supporting its financial health. The balance sheet shows a prudent approach to leverage, though improvements in return on equity could enhance investor returns.

Income Statement

UMP Healthcare Holdings Limited shows a positive revenue growth rate of 2.84% from 2023 to 2024 and maintains a strong gross profit margin of 92.48% for 2024. The net profit margin decreased slightly to 5.43% in 2024 from 8.31% in 2023, indicating some pressure on net income. The EBIT margin improved to 12.75% in 2024, reflecting better operational efficiency. Overall, the company demonstrates solid financial health in terms of revenue and operational performance.

Balance Sheet

The debt-to-equity ratio increased slightly to 0.24 in 2024, suggesting a conservative leverage strategy with manageable debt levels. Return on equity (ROE) decreased to 5.60% in 2024 from 8.16% in 2023, indicating a lower return on shareholder investment. The equity ratio stands at 65.61%, showing a strong reliance on equity financing. The balance sheet reflects a stable financial position but with room for improvement in ROE.

Cash Flow

Free cash flow increased by 13.41% in 2024, indicating strong cash generation capability. The operating cash flow to net income ratio is 3.58, showcasing effective conversion of income to cash. However, the free cash flow to net income ratio is 2.25, indicating a moderate level of free cash available relative to net income. Cash flow performance is robust, supporting operational and strategic flexibility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	727.36M	727.36M	748.49M	727.75M	666.20M	617.16M
Gross Profit	490.61M	490.61M	692.25M	502.69M	463.95M	456.28M
EBITDA	80.24M	80.24M	161.98M	178.21M	170.15M	170.44M
Net Income	31.44M	31.44M	40.64M	60.45M	72.17M	34.83M
Balance Sheet
Total Assets	1.10B	1.10B	1.11B	1.12B	1.04B	969.98M
Cash, Cash Equivalents and Short-Term Investments	341.70M	341.70M	307.49M	318.58M	291.65M	344.59M
Total Debt	161.55M	161.55M	172.57M	172.22M	148.34M	78.03M
Total Liabilities	343.53M	343.53M	362.14M	351.54M	300.30M	276.92M
Stockholders Equity	742.63M	742.63M	725.94M	740.55M	698.65M	639.50M
Cash Flow
Free Cash Flow	107.66M	0.00	91.54M	80.71M	26.40M	149.17M
Operating Cash Flow	111.99M	0.00	148.78M	190.04M	110.91M	172.67M
Investing Cash Flow	24.85M	0.00	-68.49M	-134.09M	-77.12M	-39.26M
Financing Cash Flow	-58.06M	0.00	-117.13M	-53.67M	-90.98M	-69.21M

UMP Healthcare Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.48
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0722, the sentiment is Negative. The current price of 0.48 is above the 20-day moving average (MA) of 0.47, above the 50-day MA of 0.46, and above the 200-day MA of 0.44, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 46.19 is Neutral, neither overbought nor oversold. The STOCH value of 22.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0722.

UMP Healthcare Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0722	78 Outperform	HK$380.45M	11.93	4.28%	7.10%	-2.88%	-22.83%
2293	75 Outperform	HK$197.21M	11.19	7.84%	8.00%	-21.50%	-43.25%
3689	71 Outperform	HK$601.91M	7.29	5.33%	9.14%	0.47%	50.46%
2189	65 Neutral	HK$450.00M	19.40	5.24%	4.49%	20.85%	-66.81%
1419	55 Neutral	HK$311.23M	11.82	3.40%	3.75%	9.07%	8.95%
1518	54 Neutral	HK$322.15M	-6.90	-8.40%	3.16%	-21.31%	-149.92%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

UMP Healthcare Holdings Limited Corporate Events

UMP Healthcare’s AGM Resolutions Passed Unanimously

UMP Healthcare Holdings Limited announced the successful passing of all proposed resolutions during its Annual General Meeting held on November 21, 2025. Key resolutions included the adoption of financial statements, declaration of a final dividend, re-election of directors, re-appointment of auditors, and granting of mandates for share repurchase and issuance, reflecting strong shareholder support and strategic continuity.

The most recent analyst rating on (HK:0722) stock is a Buy with a HK$0.50 price target. To see the full list of analyst forecasts on UMP Healthcare Holdings Limited stock, see the HK:0722 Stock Forecast page.

UMP Healthcare Approves New Medical Services Agreement with CTF Life

UMP Healthcare Holdings Limited announced the results of its extraordinary general meeting held on November 21, 2025, where a resolution to approve a medical services agreement with CTF Life was passed unanimously. The agreement is expected to strengthen UMP’s service capabilities and market position, although certain major shareholders abstained from voting due to regulatory requirements.

The most recent analyst rating on (HK:0722) stock is a Buy with a HK$0.50 price target. To see the full list of analyst forecasts on UMP Healthcare Holdings Limited stock, see the HK:0722 Stock Forecast page.

UMP Healthcare Announces Board and Leadership Changes

UMP Healthcare Holdings Limited announced significant changes in its board composition following the conclusion of its annual general meeting on November 21, 2025. Dr. LI Kwok Tung, Donald and Dr. LEE Kar Chung, Felix have both concluded their tenures as directors, with new appointments including Ms. CHENG Chi Man and Mrs. CHAN KUNG Wai Ying, Amy. Additionally, Mr. LEE Luen Wai, John has been redesignated as the chairman of the Remuneration Committee, and Ms. TONG Mo Ting has been appointed as the joint company secretary. These changes reflect the company’s ongoing efforts to strengthen its leadership and governance structure, potentially impacting its strategic direction and stakeholder relations.

The most recent analyst rating on (HK:0722) stock is a Buy with a HK$0.50 price target. To see the full list of analyst forecasts on UMP Healthcare Holdings Limited stock, see the HK:0722 Stock Forecast page.

UMP Healthcare Announces Board and Committee Composition

UMP Healthcare Holdings Limited has announced the composition of its board of directors and the members of its key committees, including the Audit, Remuneration, and Nomination Committees. This announcement highlights the leadership structure of the company, which may impact its strategic direction and governance, potentially influencing stakeholder confidence and the company’s positioning in the healthcare market.

The most recent analyst rating on (HK:0722) stock is a Buy with a HK$0.50 price target. To see the full list of analyst forecasts on UMP Healthcare Holdings Limited stock, see the HK:0722 Stock Forecast page.

UMP Healthcare to Discuss New Medical Services Agreement at Upcoming EGM

UMP Healthcare Holdings Limited has announced an extraordinary general meeting scheduled for November 21, 2025, to discuss and potentially approve the 2026 CTF Life Medical Services Agreement. This agreement, involving UMP Professional and CTF Life, aims to enhance the provision and administration of medical services, indicating a strategic move to strengthen UMP’s operational capabilities and market position.

The most recent analyst rating on (HK:0722) stock is a Buy with a HK$0.50 price target. To see the full list of analyst forecasts on UMP Healthcare Holdings Limited stock, see the HK:0722 Stock Forecast page.

UMP Healthcare Announces Book Closure for Upcoming EGM

UMP Healthcare Holdings Limited has announced the book closure period for its upcoming Extraordinary General Meeting (EGM) scheduled for November 21, 2025. This meeting will address continuing connected transactions related to the 2026 CTF Life Medical Services Agreement. Shareholders must ensure their share transfers are registered by November 17, 2025, to participate in the EGM. The announcement underscores the company’s ongoing strategic initiatives and engagement with shareholders, which may influence its operational and market positioning.

The most recent analyst rating on (HK:0722) stock is a Buy with a HK$0.50 price target. To see the full list of analyst forecasts on UMP Healthcare Holdings Limited stock, see the HK:0722 Stock Forecast page.

UMP Healthcare Announces AGM and Share Repurchase Mandate

UMP Healthcare Holdings Limited has announced its upcoming annual general meeting scheduled for November 21, 2025, where key agenda items include the adoption of financial statements, declaration of a final dividend, and re-election of directors. Additionally, the company seeks shareholder approval for a mandate allowing the repurchase of up to 10% of its issued shares, which could impact its financial strategy and shareholder value.

The most recent analyst rating on (HK:0722) stock is a Buy with a HK$0.50 price target. To see the full list of analyst forecasts on UMP Healthcare Holdings Limited stock, see the HK:0722 Stock Forecast page.

UMP Healthcare Expands Medical Services Through New Agreement

UMP Healthcare Holdings Limited announced a supplemental agreement regarding continuing connected transactions related to medical services. The agreement with Pedder Healthcare Group aims to enhance UMP’s service offerings by integrating specialty and surgical services, thereby strengthening its market position and providing comprehensive healthcare solutions. Payment terms will be negotiated individually to ensure favorable conditions for UMP, aligning with commercial standards.

The most recent analyst rating on (HK:0722) stock is a Buy with a HK$0.50 price target. To see the full list of analyst forecasts on UMP Healthcare Holdings Limited stock, see the HK:0722 Stock Forecast page.